Haque Waqar, Verma Vivek, Butler E Brian, Teh Bin S
Department of Radiation Oncology, Greater Houston Physicians Medical Association, Houston, TX, USA.
Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
J Gastrointest Oncol. 2018 Feb;9(1):80-89. doi: 10.21037/jgo.2017.09.12.
Neoadjuvant chemoradiotherapy (CRT) for locally advanced esophageal cancer (EC) may utilize a wide variety of RT doses, without clear consensus to date. This study evaluated national practice patterns between lower dose (LD) (40-41.4 Gy) or higher dose (HD) (50-50.4 Gy) therapy, in addition to differences in survival and postoperative events.
The National Cancer Data Base (NCDB) was queried [2004-2013] for patients with newly-diagnosed cT1a-T4aN0/N+M0 EC that received neoadjuvant CRT followed by esophagectomy. Multivariable logistic regression determined factors predictive of receiving LD RT. Kaplan-Meier analysis evaluated overall survival (OS), and Cox proportional hazards modeling determined variables associated with OS. Propensity score matching assessed groups in a balanced manner while reducing indication biases.
Altogether, 5,025 patients met inclusion criteria; 257 (5%) received LD RT, while 4,768 (95%) received HD RT. LD RT was more likely delivered at academic centers (P=0.038), in more recent years (2009-2013, P=0.011), and to squamous cell carcinomas (P=0.001). HD RT tended to be administered with higher T stage as well as node-positive disease (P<0.05). The median OS in the LD and HD cohorts was 39.0 35.6 months (P=0.072), and 39.0 42.7 months after propensity matching (P=0.812). Dose did not independently correlate with OS on multivariate analysis (P=0.069), but treatment at academic centers correlated with improved OS (P=0.028). There were no differences between groups in the rates of 30-day readmission (P=0.182), 30-day mortality (P=0.314), or length of postoperative hospital stay (P=0.665), but the LD group experienced lower 90-day mortality (P=0.007).
Although neoadjuvant LD CRT has been underutilized for EC in the United States, it is rising in more recent years. Dose did not significantly impact survival before or after propensity matching, nor did it independently predict for survival. Treatment at academic facilities independently correlated with higher survival, which has implications for patient counseling.
局部晚期食管癌(EC)的新辅助放化疗(CRT)可能采用多种放疗剂量,目前尚无明确共识。本研究评估了低剂量(LD)(40 - 41.4 Gy)或高剂量(HD)(50 - 50.4 Gy)治疗之间的全国实践模式,以及生存和术后事件的差异。
查询国家癌症数据库(NCDB)[2004 - 2013年]中初诊为cT1a - T4aN0/N + M0 EC且接受新辅助CRT后行食管切除术的患者。多变量逻辑回归确定接受LD放疗的预测因素。Kaplan - Meier分析评估总生存期(OS),Cox比例风险模型确定与OS相关的变量。倾向评分匹配以平衡的方式评估组间差异,同时减少指征偏倚。
共有5025例患者符合纳入标准;257例(5%)接受LD放疗,4768例(95%)接受HD放疗。LD放疗更可能在学术中心进行(P = 0.038),在近年(2009 - 2013年,P = 0.011),且用于鳞状细胞癌(P = 0.001)。HD放疗倾向于用于更高T分期以及淋巴结阳性疾病(P < 0.05)。LD组和HD组的中位OS分别为39.0±35.6个月(P = 0.072),倾向评分匹配后为39.0±42.7个月(P = 0.812)。多变量分析中剂量与OS无独立相关性(P = 0.069),但在学术中心治疗与OS改善相关(P = 0.028)。两组在30天再入院率(P = 0.182)、30天死亡率(P = 0.314)或术后住院时间(P = 0.665)方面无差异,但LD组90天死亡率较低(P = 0.007)。
尽管美国新辅助LD CRT在EC治疗中的应用不足,但近年来呈上升趋势。剂量在倾向评分匹配前后对生存均无显著影响,也不能独立预测生存。在学术机构治疗与较高的生存率独立相关,这对患者咨询有重要意义。